La chaîne d'options affiche les données clés des options sur actions de Corbus Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Corbus Pharmaceuticals..

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock, Chaîne d'Options

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

News

RCUS

Arcus Biosciences Receives FDA Orphan Drug Designation For Quemliclustat In Pancreatic Cancer

Keybanc analyst Justin Patterson maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1070 to $1390.

Price Target

Analyst Ratings

NFLX

Keybanc Maintains Overweight on Netflix, Raises Price Target to $1390

Goldman Sachs analyst James Schneider initiates coverage on Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Buy rating and announces Price Target of $315.

Initiation

AVGO

Goldman Sachs Initiates Coverage On Broadcom with Buy Rating, Announces Price Target of $315

In a landscape where economic resilience is constantly tested, three key insights from CNBC's &#8220;Halftime Report Final Trades&#8221; offer a glimpse into the shifting dynamics of the industrial and healthcare sectors, as well as the promising <a href="https://www.benzinga.com/topic/ecommerce">potential of e-commerce.</a>
On Wednesday&#8217;s <a href="https://www.cnbc.com/video/2025/07/09/final-trades-wabtec-unitedhealth-and-doordash.html">program</a>, Jim Lebenthal at Cerity Partners said Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) is a solid <a href="https://www.benzinga.com/quote/WAB/analyst-ratings">mid-cap industrial</a>.
Supporting his view, BofA Securities analyst Ken Hoexter maintained a Buy rating for Westinghouse Air Brake on Tuesday and raised the price target from $231 to $236.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), which fell on Wednesday, on the Wall Street Journal article.
UnitedHealth Group is facing renewed legal pressure as shareholders file additional lawsuits, many of which reference a federal investigation into the company&#8217;s Medicare billing practices, as reported by The Wall Street Journal in May.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova, senior managing director for Virtus Investment Partners, said DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) has very strong pricing power.
On the earnings front, DoorDash will release second-quarter financial results after the closing bell on Wednesday, Aug. 6. Analysts expect the company to report quarterly earnings at 43 cents per share, versus a year-ago loss of 38 cents per share.
Price Action:
<ul class="wp-block-list">
<li>Westinghouse Air Brake Technologies shares gained 0.6% to close at $213.05 on Wednesday.</li>
<li>UnitedHealth fell 1.6% to close at $302.91 during the session.</li>
<li>DoorDash shares gained 1.9% to close at $246.06 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

DASH

DoorDash, Westinghouse Air Brake Technologies And A Health Care Stock On CNBC's 'Final Trades'

Biotech

General

JAGX

Jaguar Health Announces Four Dogs Have Now Been Enrolled In Ongoing Field Study Of Canalevia-CA1

WIIM

Genius Group shares are trading higher after the company announced a share buyback approval for up to one million shares.

Goldman Sachs analyst James Schneider initiates coverage on NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy rating and announces Price Target of $185.

NVDA

Goldman Sachs Initiates Coverage On NVIDIA with Buy Rating, Announces Price Target of $185

Keybanc analyst Jason Celino maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Overweight and raises the price target from $340 to $358.

CDNS

Keybanc Maintains Overweight on Cadence Design Systems, Raises Price Target to $358

BLNK

Blink Charging And Axxeltrova Capital To Pursue £100M Special Purpose Vehicle

ZENA

ZenaTech Creates First Quantum Computing Prototype For AI Drone Solutions

Wells Fargo analyst Tiago Fauth downgrades Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) from Overweight to Equal-Weight and lowers the price target from $138 to $107.

Downgrades

VRNA

Wells Fargo Downgrades Verona Pharma to Equal-Weight, Lowers Price Target to $107

Goldman Sachs analyst James Schneider initiates coverage on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy rating and announces Price Target of $225.

AMAT

Goldman Sachs Initiates Coverage On Applied Mat with Buy Rating, Announces Price Target of $225

<a href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" title="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx">https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx</a>

MRNA

Moderna Receives Full FDA Approval for COVID-19 Vaccine, Spikevax, In Children Aged 6 Months Through 11 Years At Increased Risk For COVID-19 Disease

Macro Economic Events

Econ #s

Economics

USA Continuing Jobless Claims 1,965K Vs 1,980K Est.

Goldman Sachs analyst James Schneider initiates coverage on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Neutral rating and announces Price Target of $20.

AMKR

Goldman Sachs Initiates Coverage On Amkor Tech with Neutral Rating, Announces Price Target of $20

US Initial Jobless Claims 227K vs 236K Est.

Goldman Sachs analyst James Sheehan initiates coverage on GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral rating and announces Price Target of $40.

Goldman Sachs Initiates Coverage On GLOBALFOUNDRIES with Neutral Rating, Announces Price Target of $40

HTOO

Fusion Fuel Green shares are trading lower after the company announced a 1-for-35 reverse stock split to regain Nasdaq minimum bid price rule compliance.

Goldman Sachs analyst James Sheehan initiates coverage on Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Western Digital with Neutral Rating, Announces Price Target of $130

D. Boral Capital analyst Jesse Sobelson maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $15 price target.

EVTL

D. Boral Capital Maintains Buy on Vertical Aerospace, Maintains $15 Price Target

Press Releases

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Earnings

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Health Care

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Management

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Comments

Corbus Pharmaceuticals

Corbus Pharmaceuticals (CRBP) Options

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL